Article
Inhibition of nuclear import suppresses androgen receptor action and overcomes resistance in prostate cancer.
BMC cancer - 25 Feb 2026
Wang Xuan, Xu Xin, Fang Shengyun, Shi Xiaolei, Yang Yili
Abstract excerpt
BACKGROUND: Androgen deprivation and androgen receptor (AR) antagonists are essential treatments for prostate cancers in the clinic. However, after an initially effective response, most tumors become resistant to androgen deprivation therapies. Resistance often arises from AR mutations, resulting in ligand-independent activation and nuclear translocation of AR. METHODS: This study investigated the effects of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
